Emedgene collaborates with Illumina to scale the interpretation of genomic data for rare diseases
USA - English
News provided by
Share this article
Share this article
PALO ALTO, California, Dec. 16, 2020 /PRNewswire/ Emedgene, a leading precision medicine intelligence company, announces a non-exclusive partnership with
Illumina Inc. and the integration of automated interpretation into Illumina s TruSight™ Software Suite for rare genetic diseases. Emedgene s Clinical Rare Disease application is one of a portfolio of artificial intelligence (AI)-powered applications for high-throughput genomic interpretation across clinical and research use cases.
Healthcare is in the midst of a leap towards precision medicine. Continued improvements in the cost of next-generation sequencing (NGS) technologies, such as those developed by Illumina, have dramatically accelerated the adoption of genetic testing. Consequently, data generated from genomics doubles every year and is expected to